Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 473,657 shares, a growth of 7,658.5% from the June 30th total of 6,105 shares. Approximately 7.8% of the company’s shares are sold short. Based on an average trading volume of 2,079,462 shares, the short-interest ratio is presently 0.2 days.

Institutional Trading of Matinas Biopharma

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC purchased a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma at the end of the most recent reporting period. 11.77% of the stock is currently owned by institutional investors.

Matinas Biopharma Stock Down 3.1%

NYSEAMERICAN:MTNB opened at $0.24 on Friday. Matinas Biopharma has a 12-month low of $0.23 and a 12-month high of $3.09. The firm has a market capitalization of $1.55 million, a P/E ratio of -0.12 and a beta of 1.71. The stock’s fifty day simple moving average is $0.62 and its 200-day simple moving average is $0.61.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.30) EPS for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical?stage biopharmaceutical company that specializes in the development of novel lipid?based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water?soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life?threatening fungal infections.